Carboplatin (CBDCA) plus alpha interferon in metastatic non-small cell lung cancer

A Hoosier Oncology Group Phase II trial

R. Mandanas, Lawrence Einhorn, B. Wheeler, R. Ansari, T. Lutz, M. E. Miller

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Interferons have been shown to increase in vitro cytotoxicity of platinum compounds. The Hoosier Oncology Group has conducted a Phase II clinical trial to determine if interferon alpha-2a (IFN-α-2a) given in combination with carboplatin (CBDCA) can increase response rates or survival in patients with metastatic or recurrent inoperable non-small-cell lung cancer. Forty-four patients with no prior chemotherapy and high KPS (80-100) were enrolled. CBDCA 400 mg/m2 was given intravenously on day 1 and IFN-α-2a 9 million units was given subcutaneously on days 1, 3, and 5. Treatment was administered every 4 weeks until onset of progressive disease or to a maximum of 4 courses: 37 patients (84%) received at least 2 courses, whereas only 16 (36%) received the full 4 courses. Dose-limiting toxicities were leukopenia (27%) and thrombocytopenia (20%) attributable to CBDCA. Grade 2-3 anemia occurred in 32%. Only 4-7% of patients experienced severe fever, fatigue, or flu-like symptoms attributable to interferon administration. Of 41 patients evaluable for response, there were no complete responses and only 3 (7.3%) partial remissions. The overall median survival was 6 months. The combination of CBDCA and IFN-α-2a given in this dose and schedule does not appear to have superior activity compared to CBDCA alone in patients with non-small- cell lung cancer.

Original languageEnglish (US)
Pages (from-to)519-521
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number6
StatePublished - 1993

Fingerprint

Carboplatin
Interferon-alpha
Non-Small Cell Lung Carcinoma
Interferons
Platinum Compounds
Phase II Clinical Trials
Leukopenia
Thrombocytopenia
Fatigue
Anemia
Appointments and Schedules
Fever
Survival Rate
Drug Therapy
Survival
interferon alfa-2a

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Carboplatin (CBDCA) plus alpha interferon in metastatic non-small cell lung cancer : A Hoosier Oncology Group Phase II trial. / Mandanas, R.; Einhorn, Lawrence; Wheeler, B.; Ansari, R.; Lutz, T.; Miller, M. E.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 16, No. 6, 1993, p. 519-521.

Research output: Contribution to journalArticle

@article{2cf370a4e5724efca7e2fe365171e5bd,
title = "Carboplatin (CBDCA) plus alpha interferon in metastatic non-small cell lung cancer: A Hoosier Oncology Group Phase II trial",
abstract = "Interferons have been shown to increase in vitro cytotoxicity of platinum compounds. The Hoosier Oncology Group has conducted a Phase II clinical trial to determine if interferon alpha-2a (IFN-α-2a) given in combination with carboplatin (CBDCA) can increase response rates or survival in patients with metastatic or recurrent inoperable non-small-cell lung cancer. Forty-four patients with no prior chemotherapy and high KPS (80-100) were enrolled. CBDCA 400 mg/m2 was given intravenously on day 1 and IFN-α-2a 9 million units was given subcutaneously on days 1, 3, and 5. Treatment was administered every 4 weeks until onset of progressive disease or to a maximum of 4 courses: 37 patients (84{\%}) received at least 2 courses, whereas only 16 (36{\%}) received the full 4 courses. Dose-limiting toxicities were leukopenia (27{\%}) and thrombocytopenia (20{\%}) attributable to CBDCA. Grade 2-3 anemia occurred in 32{\%}. Only 4-7{\%} of patients experienced severe fever, fatigue, or flu-like symptoms attributable to interferon administration. Of 41 patients evaluable for response, there were no complete responses and only 3 (7.3{\%}) partial remissions. The overall median survival was 6 months. The combination of CBDCA and IFN-α-2a given in this dose and schedule does not appear to have superior activity compared to CBDCA alone in patients with non-small- cell lung cancer.",
author = "R. Mandanas and Lawrence Einhorn and B. Wheeler and R. Ansari and T. Lutz and Miller, {M. E.}",
year = "1993",
language = "English (US)",
volume = "16",
pages = "519--521",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Carboplatin (CBDCA) plus alpha interferon in metastatic non-small cell lung cancer

T2 - A Hoosier Oncology Group Phase II trial

AU - Mandanas, R.

AU - Einhorn, Lawrence

AU - Wheeler, B.

AU - Ansari, R.

AU - Lutz, T.

AU - Miller, M. E.

PY - 1993

Y1 - 1993

N2 - Interferons have been shown to increase in vitro cytotoxicity of platinum compounds. The Hoosier Oncology Group has conducted a Phase II clinical trial to determine if interferon alpha-2a (IFN-α-2a) given in combination with carboplatin (CBDCA) can increase response rates or survival in patients with metastatic or recurrent inoperable non-small-cell lung cancer. Forty-four patients with no prior chemotherapy and high KPS (80-100) were enrolled. CBDCA 400 mg/m2 was given intravenously on day 1 and IFN-α-2a 9 million units was given subcutaneously on days 1, 3, and 5. Treatment was administered every 4 weeks until onset of progressive disease or to a maximum of 4 courses: 37 patients (84%) received at least 2 courses, whereas only 16 (36%) received the full 4 courses. Dose-limiting toxicities were leukopenia (27%) and thrombocytopenia (20%) attributable to CBDCA. Grade 2-3 anemia occurred in 32%. Only 4-7% of patients experienced severe fever, fatigue, or flu-like symptoms attributable to interferon administration. Of 41 patients evaluable for response, there were no complete responses and only 3 (7.3%) partial remissions. The overall median survival was 6 months. The combination of CBDCA and IFN-α-2a given in this dose and schedule does not appear to have superior activity compared to CBDCA alone in patients with non-small- cell lung cancer.

AB - Interferons have been shown to increase in vitro cytotoxicity of platinum compounds. The Hoosier Oncology Group has conducted a Phase II clinical trial to determine if interferon alpha-2a (IFN-α-2a) given in combination with carboplatin (CBDCA) can increase response rates or survival in patients with metastatic or recurrent inoperable non-small-cell lung cancer. Forty-four patients with no prior chemotherapy and high KPS (80-100) were enrolled. CBDCA 400 mg/m2 was given intravenously on day 1 and IFN-α-2a 9 million units was given subcutaneously on days 1, 3, and 5. Treatment was administered every 4 weeks until onset of progressive disease or to a maximum of 4 courses: 37 patients (84%) received at least 2 courses, whereas only 16 (36%) received the full 4 courses. Dose-limiting toxicities were leukopenia (27%) and thrombocytopenia (20%) attributable to CBDCA. Grade 2-3 anemia occurred in 32%. Only 4-7% of patients experienced severe fever, fatigue, or flu-like symptoms attributable to interferon administration. Of 41 patients evaluable for response, there were no complete responses and only 3 (7.3%) partial remissions. The overall median survival was 6 months. The combination of CBDCA and IFN-α-2a given in this dose and schedule does not appear to have superior activity compared to CBDCA alone in patients with non-small- cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0027141063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027141063&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 519

EP - 521

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -